key: cord-0715204-ekiwl8bp
authors: Najar Nobari, Niloufar; Seirafianpour, Farnoosh; Mashayekhi, Farzaneh; Goodarzi, Azadeh
title: A systematic review on treatment‐related mucocutaneous reactions in COVID‐19 patients
date: 2020-12-26
journal: Dermatol Ther
DOI: 10.1111/dth.14662
sha: 2adb4346cd2dc8c6c2d58dba55a45e489a0c9e3c
doc_id: 715204
cord_uid: ekiwl8bp

Most of drugs could have certain mucocutaneous reactions and COVID‐19 drugs are not an exception that we focused. We systematically reviewed databases until August 15, 2020 and among initial 851 articles, 30 articles entered this study (20 case reports, 4 cohorts, and 6 controlled clinical trials). The types of reactions included AGEP, morbiliform drug eruptions, vasculitis, DRESS syndrome, urticarial vasculitis, and so on. The treatments have been used before side effects occur, included: antimalarial, anti‐viral, antibiotics, tocilizumab, enoxaparin and and so on. In pandemic, we found 0.004% to 4.15% of definite drug‐induced mucocutaneous reactions. The interval between drug usage and the eruption varied about few hours to 1 month; tightly dependent to the type of drug and hydroxychloroqine seems to be the drug with highest mean interval. Antivirals, antimalarials, azithromycin, and tocilizumab are most responsive drugs for adverse drug reactions, but antivirals especially in combination with antimalarial drugs are in the first step. Types of skin reactions are usually morbilliform/exanthematous maculopapular rashes or urticarial eruptions, which mostly may manage by steroids during few days. In the setting of HCQ, specific reactions like AGEP should be considered. Lopinavir/ritonavir is the most prevalent used drug among antivirals with the highest skin adverse reaction; ribarivin and remdisivir also could induce cutaneous drug reactions but favipiravir has no or less adverse effects. Logically the rate of dermatologic adverse effects among anivirals may relate to their frequency of usage. Rarely, potentially life‐threatening reactions may occur. Better management strategies could achieve by knowing more about drug‐induced mucocutaneous presentations of COVID‐19.

inhibitor, mucocutaneous, mucosal, novel human coronavirus (SARS-CoV-2), skin, systematic review, targeted therapy, TNF-α inhibitor, tocilizumab, treatment-induced, treatment-reaction, treatment-related 

There are few reports about treatment-related mucocutaneous drug reactions of COVID-19, but since this infection is a pandemic concern with an increasing infection rate at many areas of the world, it is expected to encounter growing reports of drug-related adverse mucocutaneous reactions, such as, HCQ-induced AGEP or flare and aggravation of psoriasis course. 2, 3 In overall, different types of drug categories, which may use for treatment of new corona virus with their own well-known dermatologic reactions also patients who are in a certain condition results from the virus and host interaction-induced immune-dysregulation and cytokine storm may provide higher tendency to emergence of well-known, new, severe and more complex mucocutaneous drug reactions or even aggravation and flare of a preexisting dermatoses. So, in this systematic review, we focused on the treatment-related mucocutaneous drug reactions of COVID-19, to discuss on the clinical presentation types, differential diagnoses, severity, course, definite diagnosis and the managements or probable challenges.

This study is implemented according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. The PRISMA flow chart has been shown in Figure S1 in the supplement file.

Inclusion criteria comprised all studies that report mucocutaneous drug reaction or skin and dermatologic manifestation in response to treatment of COVID-19 patients. PICO: population was COVID-19 patients, intervention was COVID-19 treatment, comparison was COVID-19 patients without taking any special treatment and outcome was mucocutaneous manifestations. The exclusion criteria consisted of animal studies, in vitro studies, review studies and all publications not meeting the above.

Databases PubMed (http:// pubmed.ncbi.nlm.nih.gov), Scopus (http:// www.scopus.com), Embase (https://www.embase.com) and Google Scholar (https://scholar.google.com) and CEBD Covid-19 Resource for Dermatology (https://skin.cochrane.org/news/cebd-covid-19resource-dermatology) have been searched for the evidence. 

Endnote X9 (Clarivate Analytics, Philadelphia) was used for study screening and data extraction. 851 articles assigned to the inclusion and exclusion groups. In first step, the titles and abstracts of articles were read. And, if accepted has evaluated to second step; 186 articles went to the full-text screening; the authors read the full-text and executed the final inclusion articles. Disagreement situations regarding the inclusion process resolved through dialogue and no necessity for a third-party involvement occurred.

Finally, there were 30 articles that met inclusion criteria and the information of these articles are prepared in Tables 1-4.

We have evaluated 20 case reports including 25 cases of COVID-19 who were treated with multiple drugs in Table 1 . [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In Tables 2, 4 cohort studies are shown. In cohort studies based on the drugs have been used the overall rate of mucocutaneous dermatologic eruptions ranged from 0.004% to 4.15%. Antivirals, antimalarials, azithromycin, and tocilizumab were most responsive drugs for adverse reactions. It seems that antivirals especially in combination with antimalarial drugs may have the highest rate of skin reactions. Types of skin reactions are usually morbilliform/exanthematous maculopapular rashes or urticarial eruptions. Pruritus, bullous rashes and skin dyspigmentations were other observed dermatologic adverse effects of drugs used for management of COVID-19. 24-28 Table 5 shows cohort studies reported dermatologic rashes in the setting of COVID-19 but with uncertainty about exact origin; means that exactly say about they were virus-related or drug-related. 28 The reported mucocutaneous reaction rate in these series of studies was about 5.7% to 45.5%, and the drugs were suspected as the cause of these drug reactions were mainly antimalarials, antivirals, azithromycin, systemic steroids, and tocilizumab with different prevalence distributions in various studies. Antimalarials, antivirals, azithromycin were the most prevalent drugs used for therapy and morbilliform/exanthematous maculopapular, purpuric, EM-like and PR-like eruptions were the most observed mucocutaneous reactions of these drugs. 28 In Tables 3 and 4 controlled clinical trial studies have been shown which were 5 articles with 2 arms [29] [30] [31] [32] [33] and 1 article with 3 arms. 34 It seems that favipiravir has no or less skin adverse reactions in comparison with lopinavir/ritonavir. Remdisivir could induce mucocutaneous rash but the most probable cause of skin reactions between antivirals is related to lopinavir/ritonavir (21%). Ruxolitinib is another drug may cause mucocutaneous reactions (10%). Interferon-alfa my decrease rate of dermatologic reactions of antivirals such as ribavirin or lopinavir/ritonavir based on what we observed in combination therapy regimens. Logically it should be notified that the rate of dermatologic adverse effects among anivirals may relate to their frequency of usage and since lopinavir/ritonavir at the time of data gathering of this systematic review was the most prevalent used antiviral; so it is not unexpected to see the most dermatologic reactions among antivirals by this drug. the form of vasculitis 2 days after administration of amoxicillin, ibuprofen, metamizole, intravenous prednisolone and antihistamine. 8 The skin biopsy confirmed drug-induced vasculitis. The patient was treated with high dose systemic steroid and complete remission was achieved 9 days after treatment. According to case reports studies drug dependent skin manifestations may occur a few hours to a month after taking the drug and usually last less than a week. The interval between drug usage and the eruption varies about few hours to 1 month and it is tightly dependent on the type of drug was used; hydroxychloroquine seems to be the drug with highest mean interval. 

Given that the drugs used to treat COVID-19 could potentially have several side effects, the incidence of mucocutaneous drug reactions in these patients is not unexpected. In this pandemic, during treatment with common therapeutic protocols for COVID-19, numerous dermatologic drug side effects should be considered and more investigate for better diagnoses and approaches especially regarding the point that large number of the patients may visit by physicians of multiple services, so logically knowing more about the mentioned presentations is really of great value for many subspecialists even other than the dermatologists.

Since the lack of enough evidence about treatment-related mucocutaneous drug reactions of COVID-19, we decided to systematically search the literature for these types of dermatologic reactions. In future perspective we expect encounter to growing reports of drug-related adverse mucocutaneous reactions of COVID-19, which could be wellknown, new, severe or more complex due to the pandemic concerns, new-emerging proposed therapies, increasing infection rate of new corona virus at many areas of the world and also virus-host induced certain immune abnormalities that may affect the nature of the drug reactions. We found that drug reactions in patients with COVID-19 could be common and skin side effects is not an exception due to the multiplicity of drugs and the type of drugs are used so the risk of drug reactions with these drugs should be considered in any prescription treatment.

We found 0.004% to 4.15% of definite drug-induced mucocutaneous reactions in pandemic area. The interval between drug usage and the eruption varies about few hours to 1 month tightly dependent to the type of drug and usually last less than a week; hydroxychloroqine seems to be the drug with highest mean interval.

Antivirals, antimalarials, azithromycin and tocilizumab are most responsive drugs for adverse drug reactions, but antivirals especially in combination with antimalarial drugs are in the first step. Types of skin reactions are usually morbilliform/exanthematous maculopapular rashes and urticarial eruptions which mostly may manage by steroids during few days. In the setting of HCQ, specific reactions like AGEP should be considered. lopinavir/ritonavir is the most prevalent used drug with the highest skin adverse reaction among antivirals; ribarivin and remdisivir also could induce cutaneous drug reactions but favipiravir has no or less adverse effects. It should be notified that logically the rate of dermatologic adverse effect among antivirals is related to their frequency of usage, too. Although very rare, we may encounter challenging sever or potentially life threatening mucocutaneous adverse drug reaction. Knowing more about the probable druginduced mucocutaneous presentations of COVID-19, is really of great value for better management of encountered cases.

Cutaneous sıde-effects of the potential COVID-19 drugs

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic?

Generalized pustular figurate erythema: a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine

Toxic erythema" and eosinophilia associated to tocilizumab therapy in a COVID-19 patient

Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman

Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine

A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?

Drug-induced vasculitis in a patient with COVID-19

Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine

Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19

SDRIFE-like rash associated with COVID-19, clinicopathological correlation

COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir

Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19

First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test

Hydroxychloroquine-Induced Stevens-Johnson Syndrome in COVID-19: A rare Case Report

A case of erythema multiforme major in a patient with COVID 19: the role of corticosteroid treatment

Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital-implications for clinical practice

Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19

A case of cefditoren-induced acute generalized Exanthematous Pustulosis during COVID-19 pandemics. Severe cutaneous adverse reactions (SCARs) are an issue

Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France

Incidence of adverse drug reactions in COVID-19 patients in China: an active monitoring study by hospital pharmacovigilance system

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

Lopinavir-ritonavir vs hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019

Maculopapular eruptions associated to COVID-19: a subanalysis of the COVID-Piel study

Experimental treatment with favipiravir for COVID-19: an open-label control study

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post_-treatment hospitalisation status

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial

No statistically apparent difference in antiviral effectiveness observed among ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate coronavirus disease 2019: results of a randomized, openlabeled prospective study

Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review

Adverse effects of antiretroviral treatment

Cutaneous manifestations in COVID-19: a first perspective

Azithromycin induced bullous fixed drug eruption

Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review

Hydroxychloroquine-induced unusual generalized Pustular cutaneous reaction as a new clinical entity: a case series

Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: a systematic review

Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? A systematic review

Treatment of COVID-19 with pentoxifylline: could it be a potential adjuvant therapy?

Comparison of long-pulsed alexandrite laser and topical tretinoin-ammonium lactate in axillary acanthosis nigricans: a case series of patients in a beforeafter trial

Systemic retinoids in the COVID-19 era-are they helpful, safe, or harmful? A comprehensive systematized review study

Cytokine storm and probable role of immunoregulatorydrugs in COVID-19: a comprehensive review study

N-acetylcysteine and coronavirus disease 2019: may it work as a beneficial preventive and adjuvant therapy? A comprehensive review study

Supporting Information section at the end of this article. How to cite this article

The authors would like to thank RasoulAkram Hospital Clinical research development Center (RCRDC) for its technical and editorial assists.

The authors declare no potential conflict of interest.

The authors contribute equally to all stages of this study. The team has reviewed the manuscript and the data, and all contributors were in full agreement.

The data that support the findings of this study are available from the corresponding author upon reasonable request.